$15.700
-0.851 (-5.42%)At close
- High
- 17.000
- Open
- 16.720
- VWAP
- 16.00
- Vol
- 1.07M
- Mkt Cap
- 20.45M
- Low
- 15.300
- Amount
- 17.11M
- EV/EBITDA, TTM
- 0.00
GlycoMimetics, Inc. is a biotechnology company. The Company has no ongoing operations, is not performing any research and development, and is preserving cash until the contemplated merger and private placement. The Company was developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation.
Analyst Ratings (5)
Cantor Fitzgerald
—
2025-03-21
Cantor Fitzgerald
2025-03-21
Price Target
—
TD Cowen
—
2024-07-26
TD Cowen
2024-07-26
Price Target
—
HC Wainwright & Co.
—
2024-06-04
HC Wainwright & Co.
2024-06-04
Price Target
—
HC Wainwright & Co.
—
2024-05-06
HC Wainwright & Co.
2024-05-06
Price Target
—
HC Wainwright & Co.
$8
2024-03-27
HC Wainwright & Co.
2024-03-27
Price Target
$8
Valuation Metrics
Events Timeline
News
9.006-15TipRanksUpcoming Stock Splits This Week (June 16 to June 20) – Stay Invested
2.006-11BenzingaGameStop Posts Weak Revenue, Joins American Superconductor, GitLab And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
9.506-11BenzingaWhy Stitch Fix Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
8.506-05NewsfilterGlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals
7.005-18GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, LRFC, RDW, GLYC on Behalf of Shareholders
GLYC FAQ — answered by Alphio AI
GlycoMimetics, Inc. is a biotechnology company. The Company has no ongoing operations, is not performing any research and development, and is preserving cash until the contemplated merger and private placement. The Company was developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
5 analysts cover GLYC: 5 rate it Buy, 0 Hold and 0 Sell.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.